Two drugs tested in adults and children with a BRAF V600 gene change
Official title: DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial tests if two known cancer drugs help more cancers that share one gene change.
Read our full plain-language summary
What the trial team says
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in children with glioma (a type of brain tumour). This means they have gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Dabrafenib and trametinib work in patients with a particular mutation in their cancer known as BRAF V600. Investigators now wish to find out if they will be useful in treating patients with other cancer types which have the same mutation. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future. This trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.
Key facts
- Registry number
- NCT07440290
- Stage of testing
- Phase 2/Phase 3
- Conditions studied
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Gastrointestinal Cancer, Non-Melanoma Skin Cancer (NMSC), Langerhans Cell Histiocytosis (LCH), Cancer, Erdheim-Chester Disease, Thyroid Carcinoma, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small Cell-Lung, Glioma, Multiple Myeloma, Thyroid Carcinoma, Anaplastic, Solid Tumour, Pancreatic Diseases
Where it is running
This trial lists 27 sites.
-
United Kingdom
- Belfast City Hospital (Belfast)
- University Hospital Birmingham (Birmingham)
- Birmingham Children's Hospital (Birmingham)
- Bristol Royal Hospital for Children (Bristol)
- Bristol Haematology and Oncology Centre (Bristol)
- Addenbrooke's Hospital (Cambridge)
- Velindre Cancer Centre (Cardiff)
- Cardiff Children's Hospital (Cardiff)
- Western General Hospital (Edinburgh)
- The Beatson Hospital (Glasgow)
- Royal Hospital for Children Glasgow (Glasgow)
- Leicester Royal Infirmary (Leicester)
- and 15 more in United Kingdom
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.